Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis of COO stock:

Technical Analysis

The stock is currently trading at $93.62 in the post-market session, showing minimal movement with a -0.01% change. The RSI-14 reading of 43.80 indicates neutral momentum, though slightly leaning towards oversold territory. The stock is trading below its 20-day moving average of $94.87, suggesting near-term weakness.

Fundamental Analysis According to recent reports, The Cooper Companies (COO) has been underperforming:

• Market cap: $19.5 billion
• Stock declined 17.7% from 52-week high of $112.38
• Q4 2024 results showed mixed performance with EPS of $1.04 beating estimates by 4%
• Revenue of $1 billion marginally missed consensus expectations

Key Challenges

• Declining PARAGUARD sales due to increased competition
• Lower demand for torics and multifocals
• U.S. inventory reduction impacting myopia management sales
• Sales growth slowdown expected in first half of fiscal 2025

Analyst Sentiment

Wall Street maintains a "Strong Buy" rating with 11 Strong Buy and 4 Hold recommendations. The average price target is $116.08, suggesting a 16.7% upside potential from current levels.

Recommendation Given the current technical weakness and near-term headwinds, but strong analyst conviction and long-term potential, investors should hold existing positions but wait for better entry points before establishing new ones.

Based on the provided data and recent market analysis, here's the price prediction for Cooper Companies (COO) stock in 2025:

The stock is expected to reach $116.69 by end of 2025, representing a 25.73% upside from the current price of $93.62, driven by strong analyst consensus and improving fundamentals. The company's projected fiscal 2025 EPS of $3.98 shows a healthy 7.9% growth from fiscal 2024, indicating sustained earnings momentum. Despite recent underperformance due to declining PARAGUARD sales and increased competition, Wall Street maintains a "Strong Buy" rating with 11 out of 15 analysts recommending Strong Buy.

The S1 support level for COO Stock is $93.78 ,The R1 resistant level for COO Stock is $98.88.

As of the end of day on 2025-02-11, the price of COO Stock was $93.28.

The target price for COO Stock according to analyst rating is 114.40, with the highest price target at 120.00 and the lowest at 102.00. Analysts have a Moderate Buy rating on COO Stock overall.

The market cap of COO is $18.6B.

Based on the provided data and current market conditions, here's a concise analysis of COO's valuation:

Valuation Analysis: COO appears overvalued based on several key metrics:

1. The stock's PE ratio of 53.47 is significantly higher than industry averages, indicating premium pricing.

2. EV/EBITDA of 21.58 suggests an elevated enterprise value relative to operating performance.

3. Price-to-Sales ratio of 9.41 indicates the market is pricing in substantial growth expectations that may be difficult to achieve.

Market Performance: The stock has underperformed significantly:

1. Down 17.7% from its 52-week high of $112.38.

2. Currently trading at $93.62, below both 50-day and 200-day moving averages, indicating bearish technical trends.

Business Challenges:

1. Declining PARAGUARD sales due to increased competition.

2. Softness in torics and multifocals demand.

3. U.S. inventory reduction impacting myopia management sales.

Despite analyst optimism with a "Strong Buy" consensus, the current valuation multiples and operational challenges suggest the stock is overvalued at current levels.

The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and women’s health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within women’s health. CooperSurgical’s brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.

Based on the provided data and references, I'll analyze COO's potential price in 2030:

The Cooper Companies (COO) stock is projected to reach $145-155 by 2030, driven by its strong market position in contact lenses and medical devices, with consistent revenue growth and strategic expansions in myopia management.

The company's focus on R&D and strategic acquisitions, combined with its projected EPS growth of 7.9% annually through 2025, suggests sustained long-term growth potential that could support this price target.

Recent analyst consensus maintains a "Strong Buy" rating with near-term price targets around $116, indicating steady upward momentum that could compound over the five-year period to 2030.

COO has a total of 15000 employees.